Insider Buying: Phillip Md Et Al Frost Purchases 25,000 Shares of Opko Health Stock (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 25,000 shares of the company’s stock in a transaction dated Thursday, August 21st. The shares were purchased at an average price of $8.81 per share, with a total value of $220,250.00. Following the acquisition, the chief executive officer now directly owns 2,012,377 shares of the company’s stock, valued at approximately $17,729,041. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Opko Health (NYSE:OPK) traded down 0.39% during mid-day trading on Friday, hitting $8.7858. 293,485 shares of the company’s stock traded hands. Opko Health has a 1-year low of $7.32 and a 1-year high of $12.95. The stock has a 50-day moving average of $8.92 and a 200-day moving average of $8.82. The company’s market cap is $3.771 billion.
Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.06) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the prior year, the company posted ($0.01) earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts predict that Opko Health will post $-0.31 earnings per share for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Finally, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Opko Health has a consensus rating of “Buy” and an average target price of $12.00.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.